412 related articles for article (PubMed ID: 32440190)
1. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors.
Troncone E; Marafini I; Del Vecchio Blanco G; Di Grazia A; Monteleone G
Clin Exp Gastroenterol; 2020; 13():131-139. PubMed ID: 32440190
[TBL] [Abstract][Full Text] [Related]
2. Innovations in Oral Therapies for Inflammatory Bowel Disease.
Ma C; Battat R; Dulai PS; Parker CE; Sandborn WJ; Feagan BG; Jairath V
Drugs; 2019 Aug; 79(12):1321-1335. PubMed ID: 31317509
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
[TBL] [Abstract][Full Text] [Related]
4. User's guide to JAK inhibitors in inflammatory bowel disease.
Spiewak TA; Patel A
Curr Res Pharmacol Drug Discov; 2022; 3():100096. PubMed ID: 35300073
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. JAK Inhibition: The Most Promising Agents in the IBD Pipeline?
Fernández-Clotet A; Castro-Poceiro J; Panés J
Curr Pharm Des; 2019; 25(1):32-40. PubMed ID: 30950344
[TBL] [Abstract][Full Text] [Related]
7. An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF-α, interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor.
Sarangi SC; Pattnaik SS; Sinha S; R G
Expert Rev Gastroenterol Hepatol; 2023; 17(8):837-861. PubMed ID: 36469630
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
9. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.
Antonelli E; Torti G; Bassotti G
J Clin Gastroenterol; 2019 Oct; 53(9):635-640. PubMed ID: 31373941
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Yarur A; Giles DA; Yeasmin S; Lundborg L; Sandborn WJ; Patel DR; Rivera-Nieves J
Front Pharmacol; 2019; 10():212. PubMed ID: 30930775
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
Palasik BN; Wang H
J Pharm Pract; 2021 Dec; 34(6):913-921. PubMed ID: 32873116
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment.
Dudek P; Fabisiak A; Zatorski H; Malecka-Wojciesko E; Talar-Wojnarowska R
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884361
[TBL] [Abstract][Full Text] [Related]
15. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.
Liu E; Aslam N; Nigam G; Limdi JK
Drugs Context; 2022; 11():. PubMed ID: 35462642
[TBL] [Abstract][Full Text] [Related]
17. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models.
Moon SY; Kim KD; Yoo J; Lee JH; Hwangbo C
Molecules; 2021 May; 26(9):. PubMed ID: 34068714
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
Ma C; Lee JK; Mitra AR; Teriaky A; Choudhary D; Nguyen TM; Vande Casteele N; Khanna R; Panaccione R; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2019 Jul; 50(1):5-23. PubMed ID: 31119766
[TBL] [Abstract][Full Text] [Related]
19. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Danese S; Argollo M; Le Berre C; Peyrin-Biroulet L
Gut; 2019 Oct; 68(10):1893-1899. PubMed ID: 31227590
[TBL] [Abstract][Full Text] [Related]
20. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
